Revance Therapeutics CEO Mark Foley's 2020 pay falls 49% to $8.8M
Revance Therapeutics reports 2020 executive compensation
By ExecPay News
Published: March 24, 2021
Revance Therapeutics reported fiscal year 2020 executive compensation information on March 24, 2021.
In 2020, five executives at Revance Therapeutics received on average a compensation package of $4.7M, a 5% increase compared to previous year.
Average pay of disclosed executives at Revance Therapeutics
Mark J. Foley, Chief Executive Officer, received $8.8M in total, which decreased by 49% compared to 2019. 89% of Foley's compensation, or $7.8M, was in stock awards. Foley also received $328K in non-equity incentive plan, $650K in salary, as well as $8.3K in other compensation.
For fiscal year 2020, the median employee pay was $254,090 at Revance Therapeutics. Therefore, the ratio of Mark J. Foley's pay to the median employee pay was 35 to one.
Dwight Moxie, General Counsel, received a compensation package of $4.5M. 57% of the compensation package, or $2.6M, was in option awards.
Abhay Joshi, Chief Operating Officer, earned $4.1M in 2020, a 113% increase compared to previous year.
Dustin Sjuts, Chief Commercial Officer, received $3.2M in 2020, which increases by 302% compared to 2019.
Tobin C. Schilke, Chief Financial Officer, earned $3M in 2020, a 196% increase compared to previous year.
Related executives
You may also like
Source: SEC filing on March 24, 2021.